<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065879</url>
  </required_header>
  <id_info>
    <org_study_id>COVAX (HT/DM)-Beijing</org_study_id>
    <nct_id>NCT05065879</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes</brief_title>
  <official_title>A Post-marketing Clinical Study of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Beijing): Immunogenicity and Safety Assessments in Patients With Hypertension and/or Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Institute of Biological Products Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the post-marketing immunogenicity and safety of the inactivated severe acute&#xD;
      respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Vero cells) in patients aged 60&#xD;
      years or older with hypertension and/or diabetes, thus to further collect the immunogenicity&#xD;
      and safety data of this product in special populations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After giving informed consent, patients with hypertension, patients with diabetes, patients&#xD;
      with both diseases, and healthy controls, all aged 60 years or older, were given two doses of&#xD;
      the inactivated SARS-CoV-2 vaccine (Vero cells). Venous blood samples were collected before&#xD;
      the first dose and on day 28 after the second dose to evaluate the immunogenicity of the&#xD;
      vaccine. Adverse events were actively recorded on a diary card once daily from day 0 to day 7&#xD;
      and once from day 8 to day 21 after the first dose and the second dose. Within 3 months after&#xD;
      immunization with the second dose and collection of diary cards, the subjects were followed&#xD;
      up by phone once a month as well as self-report to collect serious adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Serum testing technicians will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>Up to 28 days after the second dose</time_frame>
    <description>the rate of positive seroconversion against coronavirus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody level</measure>
    <time_frame>Up to 28 days after the second dose</time_frame>
    <description>neutralizing antibody level against coronavirus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events following vaccination</measure>
    <time_frame>up to 6 months</time_frame>
    <description>analyse the incidence of adverse events following immunization, both solicited and unsolicited</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1440</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Hypertension group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertension group will enroll 330 subjects with hypertension (aged 60 years or older).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetes group will enroll 330 subjects with diabetes (aged 60 years or older).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Diseases group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Diseases group will enroll 300 subjects with both hypertension and diabetes (aged 60 years or older).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy people group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy people group will enroll 480 subjects with no medical history of hypertension or diabetes (aged 60 years or older).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVAX</intervention_name>
    <description>2 doses of Covid-19 vaccine</description>
    <arm_group_label>Combined Diseases group</arm_group_label>
    <arm_group_label>Diabetes group</arm_group_label>
    <arm_group_label>Healthy people group</arm_group_label>
    <arm_group_label>Hypertension group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥60 years old individuals with full civil capacity.&#xD;
&#xD;
          -  Clinically confirmed body temperature of &lt;37.3°C before enrolling in this study.&#xD;
&#xD;
          -  Able and willing to participate in the study plan during the entire study and&#xD;
             follow-up period.&#xD;
&#xD;
          -  Capable of understanding the study procedures, willing to sign the informed consent&#xD;
             form, and able to comply with the requirements of the clinical study protocol.&#xD;
&#xD;
          -  Inclusion criteria for patients with hypertension and/or diabetes: Hypertension and/or&#xD;
             diabetes definitively diagnosed by a community-level or higher medical institution.&#xD;
             Patients with hypertension: systolic pressure &lt;160 mmHg and diastolic pressure &lt;100&#xD;
             mmHg on the day of immunization achieved by lifestyle adjustment and/or drug&#xD;
             treatment; patients with diabetes: fasting glucose ≤13.9 mmol/L on the day of (or&#xD;
             within 3 days before) immunization achieved by lifestyle adjustment and/or drug&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously confirmed or asymptomatic COVID-19 patient.&#xD;
&#xD;
          -  Has been immunized with a SARS-CoV-2 vaccine.&#xD;
&#xD;
          -  Illiterate.&#xD;
&#xD;
          -  Known allergy to any ingredient (including excipient) of this product.&#xD;
&#xD;
          -  Received non-specific immunoglobulin injection within 1 month before enrollment.&#xD;
&#xD;
          -  Received a live attenuated vaccine within 1 month before immunization or other vaccine&#xD;
             within 14 days before immunization.&#xD;
&#xD;
          -  Previous serious allergy to vaccine (e.g., acute allergic reaction, urticaria,&#xD;
             angioedema, and dyspnea).&#xD;
&#xD;
          -  Has uncontrolled epilepsy and other progressive neurological disorders; history of&#xD;
             Guillain-Barré syndrome.&#xD;
&#xD;
          -  Severe respiratory disorders, severe hepatic and renal diseases, malignancies, and&#xD;
             various acute diseases or acute onset of chronic diseases.&#xD;
&#xD;
          -  Diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma,&#xD;
             leukemia, or other autoimmune diseases.&#xD;
&#xD;
          -  Definitively diagnosed with thrombocytopenia or history of other coagulation disorders&#xD;
             that may cause subcutaneous injection to be contraindicated.&#xD;
&#xD;
          -  Currently experiencing acute complications (ketoacidosis, hyperosmolar state, lactic&#xD;
             acidosis, etc.) of diabetes; or within 2 weeks after recovery from these&#xD;
             complications.&#xD;
&#xD;
          -  Other physical conditions judged by the investigator that render the patient&#xD;
             unsuitable for participation in the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>FangJun LI</last_name>
    <phone>+86-13574109585</phone>
    <email>ymlc05@hncdc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nan'an Center for Disease Control and Prevention</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Siqun HU</last_name>
      <phone>+86-15880960857</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yong'an Center for Disease Control and Prevention</name>
      <address>
        <city>Sanming</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Youxi Center for Disease Control and Prevention</name>
      <address>
        <city>Sanming</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiulan JI</last_name>
      <phone>+86-13338238711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Songtao Miao Autonomous County Center for Disease Control and Prevention</name>
      <address>
        <city>Tongren</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie TAN</last_name>
      <phone>+86-18311709889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linli County Center for Disease Control and Prevention</name>
      <address>
        <city>Changde</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuping QI</last_name>
      <phone>+86-13786619328</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

